Table 1 Summary of the FDA approved monoclonal antibodies for treatment of solid tumors
mAB | Name | Type | Target | FDA approveda |
|---|---|---|---|---|
Trastuzumab | Herceptin® | Humanized | HER2 | HER2-positive metastatic/non-metastatic breast cancer HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma |
Pertuzumab | Perjeta® | Humanized | HER2 | HER2-positive metastatic breast cancer HER2-positive, locally advanced, inflammatory, or early stage breast cancer |
Cetuximab | Erbitux® | Chimeric | EGFR | Metastatic CRC HNSCC |
Panitumumab | Vectibix® | Human | EGFR | Metastatic CRC |
Necitumumab | Portrazzaâ„¢ | Human | EGFR | Metastatic squamous NSCLC |
Dinutuximab | Unituxinâ„¢ | Chimeric | GD2 | Pediatric high risk neuroblastoma |
Bevacizumab | Avastin® | Humanized | VEGF-A | Metastatic CRC Recurrent or metastatic non-squamous NSCLC HER2-negative metastatic breast cancer (revoked in 2011) Metastatic renal cell carcinoma Persistent, recurrent or metastatic cervical cancer Glioblastoma Recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer |
Ramucirumab | Ciramza® | Human | VEGFR-2 | Advanced or metastatic gastric or gastroesophageal junction adenocarcinoma Metastatic NSCLC Metastatic CRC |
Olaratumab | Lartruvo® | Human | PDGFR-α | Soft tissue sarcoma |
Ipilimumab | Yervoy® | Human | CTLA-4 | Unresectable or metastatic melanoma Cutaneous melanoma |
Nivolumab | Opdivo® | Human | PD-1 | Unresectable or metastatic melanoma Metastatic squamous NSCLC Metastatic NSCLC Advanced RCC Recurrent or metastatic HNSCC |
Pembrolizumab | Keytruda® | Humanized | PD-1 | Unresectable or metastatic melanoma Metastatic NSCLC Recurrent or metastatic HNSCC |
Atezolizumab | Tecentriqâ„¢ | Humanized | PD-L1 | Locally advanced or metastatic urothelial carcinoma Metastatic NSCLC |
Ado-trastuzumab emtansineb | Kadcyla® | Humanized | HER2 | HER2-positive metastatic breast cancer |
Denosumab | Xgeva® | Human | RANKL | Bone metastases from solid tumors |